[Pituitary gland tumors].
Hypophysentumoren.
Adenoma
Differential diagnosis
Dynamic magnetic resonance imaging
Endocrinological symptoms
Sella turcica region
Journal
Der Radiologe
ISSN: 1432-2102
Titre abrégé: Radiologe
Pays: Germany
ID NLM: 0401257
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
pubmed:
20
7
2019
medline:
23
11
2019
entrez:
20
7
2019
Statut:
ppublish
Résumé
In this article, the most common pituitary gland tumors and the various differential diagnoses with focus on (neuro-)radiological diagnostic criteria are presented. An intensive, selective search of the literature in PubMed was carried out. Pituitary adenomas account for approximately 10-15% of all intracranial brain tumors and are the most common tumors of the sellar region. Beyond a size of 10 mm they are called macroadenomas, under 10 mm microadenomas. They can be distinguished into hormone-active and non-active adenomas. Most of the hormone-active adenomas secrete prolactin (50%), more rarely somatotropin (10%) or corticotropin (5%). Tumors in the sellar region can arise from various tissues. Due to the anatomically complex location, local adjacent structures can be affected or compressed by the tumors. Particularly in case of suprasellar extension, visual impairment due to pressure on the optic chiasm is common. Important differential diagnoses for sellar tumors include craniopharyngiomas, meningiomas, metastases, aneurysms and Rathke cleft cysts. The task of image diagnostics is the early detection of the lesions as well as the proliferation pattern into perifocal structures. Gold standard is the thin-section, contrast-enhanced MRI examination. Dynamic contrast administration is crucial for the diagnosis of the microadenoma and the specific enhancement characteristic of some other tumors. A highly focused imaging protocol is important for the diagnosis of sellar lesions such as pituitary tumors. The current favored modality is contrast-enhanced MRI, preferably with dynamic contrast-enhanced T1-weighted sequences. Early detection of the lesions and identification of the precise anatomical location are of great importance for diagnosis and therapy.
Sections du résumé
BACKGROUND
BACKGROUND
In this article, the most common pituitary gland tumors and the various differential diagnoses with focus on (neuro-)radiological diagnostic criteria are presented.
MATERIALS AND METHODS
METHODS
An intensive, selective search of the literature in PubMed was carried out.
RESULTS
RESULTS
Pituitary adenomas account for approximately 10-15% of all intracranial brain tumors and are the most common tumors of the sellar region. Beyond a size of 10 mm they are called macroadenomas, under 10 mm microadenomas. They can be distinguished into hormone-active and non-active adenomas. Most of the hormone-active adenomas secrete prolactin (50%), more rarely somatotropin (10%) or corticotropin (5%). Tumors in the sellar region can arise from various tissues. Due to the anatomically complex location, local adjacent structures can be affected or compressed by the tumors. Particularly in case of suprasellar extension, visual impairment due to pressure on the optic chiasm is common. Important differential diagnoses for sellar tumors include craniopharyngiomas, meningiomas, metastases, aneurysms and Rathke cleft cysts. The task of image diagnostics is the early detection of the lesions as well as the proliferation pattern into perifocal structures. Gold standard is the thin-section, contrast-enhanced MRI examination. Dynamic contrast administration is crucial for the diagnosis of the microadenoma and the specific enhancement characteristic of some other tumors.
CONCLUSION
CONCLUSIONS
A highly focused imaging protocol is important for the diagnosis of sellar lesions such as pituitary tumors. The current favored modality is contrast-enhanced MRI, preferably with dynamic contrast-enhanced T1-weighted sequences. Early detection of the lesions and identification of the precise anatomical location are of great importance for diagnosis and therapy.
Identifiants
pubmed: 31321467
doi: 10.1007/s00117-019-0570-1
pii: 10.1007/s00117-019-0570-1
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
982-991Références
Neurosurg Clin N Am. 2012 Oct;23(4):529-42
pubmed: 23040741
AJNR Am J Neuroradiol. 2011 Dec;32(11):2067-72
pubmed: 21960498
Clin Neurol Neurosurg. 2007 Feb;109(2):111-24
pubmed: 17126479
Neuroradiology. 1997 Aug;39(8):571-6
pubmed: 9272494
JAMA. 2017 Feb 7;317(5):516-524
pubmed: 28170483
Asian J Neurosurg. 2018 Jan-Mar;13(1):1-8
pubmed: 29492113
Neurosurg Focus. 2010 Apr;28(4):E5
pubmed: 20367362
AJNR Am J Neuroradiol. 1997 Mar;18(3):551-4
pubmed: 9090422
AJNR Am J Neuroradiol. 2009 Oct;30(9):1766-72
pubmed: 19628625
Oncol Lett. 2016 Nov;12(5):3417-3422
pubmed: 27900014
AJR Am J Roentgenol. 1988 Sep;151(3):567-75
pubmed: 3261519
Rofo. 2013 Sep;185(9):789-93
pubmed: 23999745
Pol J Radiol. 2010 Apr;75(2):88-93
pubmed: 22802782
Neuroimaging Clin N Am. 2005 Feb;15(1):203-19
pubmed: 15927868
J Neurosci Rural Pract. 2012 Sep;3(3):286-93
pubmed: 23188980
Neurosurgery. 1998 Jan;42(1):7-16; discussion 16-7
pubmed: 9442498
World Neurosurg. 2014 Nov;82(5):781-90
pubmed: 24915069
Pediatr Neurosurg. 1991-1992;17(6):284-303
pubmed: 1668642
Eur J Radiol. 2019 Jul;116:106-115
pubmed: 31153551
Endocr Pract. 2011 Jul-Aug;17 Suppl 3:41-6
pubmed: 21613050
World Neurosurg. 2016 Jul;91:675.e1-4
pubmed: 27126911
Eur J Radiol. 2002 Feb;41(2):131-5
pubmed: 11809542
Eur J Cancer. 2019 May;113:10-13
pubmed: 30954881
Endocr Dev. 2012;23:1-15
pubmed: 23182816
World Neurosurg. 2018 Jan;109:307-327
pubmed: 29045855